JNJ
NYSEHealthcareJohnson & Johnson
Last 60 sessions
2026-11-12 21:00 UTC
Indicator panel
EMA 21
$272.07
EMA 50
$267.21
EMA 200
$247.61
RSI 14
64.0
70 overbought · 30 oversold
RVOL
1.18x
vs 20-session average
ADX 14
24.5
DI+ 38.7 · DI- 20.1
MACD
5.00
Signal 3.48
52w high
$286.07
52w low
$193.45
Price performance
1 week
+4.1%
1 month
+11.7%
3 months
+8.9%
6 months
+22.8%
1 year
+45.2%
Levels and risk
Support
$251.17
Resistance
$282.73
Volatility (ann.)
24.9%
Max drawdown (6m)
-10.7%
Support and resistance come from the pivot bands of the last 60 sessions. They are descriptive levels, not price targets.
Data still to connect
- Company fundamentals (revenue, EPS, market cap) need a licensed fundamentals provider — not connected.
- Earnings calendar, company news and SEC filings need news/SEC data providers — not connected.
Technicals computed from 251 daily bars (USD, delayed). Research and education only — not personalised investment advice.
Five analysts consensus
73/ 100
SableTrend Analyst
EMA 21 / 50 / 200
Bullish88- Price above EMA 21 ($272.07).
- EMA 21 above EMA 50 — short-term structure intact.
- EMA 50 above EMA 200 — primary uptrend.
- EMA 21 rising over the last ten sessions.
VeraMomentum Analyst
RSI 14
Bullish91- RSI 64.0 — strong momentum without exhaustion.
- RSI rising over the last week.
RhodesVolume Analyst
Relative Volume
Neutral59- Volume 1.18x its 20-session average.
VesperStrength Analyst
ADX 14 · DI+ / DI-
Neutral52- ADX 24.5 — trend still developing.
CyrusMaster Expert
MACD 12 / 26 / 9
Bullish74- MACD above its signal line, histogram cooling at 1.52.
- MACD line above zero — medium-term momentum positive.
Read it as a desk
Sable reads structure, Vera reads momentum, Rhodes reads participation, Vesper reads trend strength and Cyrus ties the four into one MACD-led verdict. When they disagree, the score stays near the middle on purpose — the desk does not force a call.
Compare against the full scan